Phase II Study to Evaluate the Safety and Efficacy of the Treatment With Pentostatin, Cyclophosphamide and Rituximab Followed by Rituximab Maintenance in Previously Untreated and Relapsed Patients With Immunocytoma/Morbus Waldenstrom, B-CLL and Other Indolent B-Cell Lymphomas.

Trial Profile

Phase II Study to Evaluate the Safety and Efficacy of the Treatment With Pentostatin, Cyclophosphamide and Rituximab Followed by Rituximab Maintenance in Previously Untreated and Relapsed Patients With Immunocytoma/Morbus Waldenstrom, B-CLL and Other Indolent B-Cell Lymphomas.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Pentostatin (Primary) ; Cyclophosphamide; Rituximab
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Acronyms PERLL
  • Most Recent Events

    • 30 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top